KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Q4 2025 value amounting to $519.2 million.

  • Regeneron Pharmaceuticals' Gains from Investment Securities rose 10489.34% to $519.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $532.1 million, marking a year-over-year decrease of 4829.46%. This contributed to the annual value of $532.1 million for FY2025, which is 4829.46% down from last year.
  • As of Q4 2025, Regeneron Pharmaceuticals' Gains from Investment Securities stood at $519.2 million, which was up 10489.34% from -$4.8 million recorded in Q3 2025.
  • Regeneron Pharmaceuticals' Gains from Investment Securities' 5-year high stood at $1.2 billion during Q4 2022, with a 5-year trough of -$347.1 million in Q2 2021.
  • For the 5-year period, Regeneron Pharmaceuticals' Gains from Investment Securities averaged around $249.1 million, with its median value being $124.8 million (2023).
  • Over the last 5 years, Regeneron Pharmaceuticals' Gains from Investment Securities had its largest YoY gain of 261413.43% in 2021, and its largest YoY loss of 18333.73% in 2021.
  • Quarter analysis of 5 years shows Regeneron Pharmaceuticals' Gains from Investment Securities stood at $768.1 million in 2021, then skyrocketed by 62.19% to $1.2 billion in 2022, then plummeted by 63.23% to $458.1 million in 2023, then crashed by 44.68% to $253.4 million in 2024, then skyrocketed by 104.89% to $519.2 million in 2025.
  • Its Gains from Investment Securities was $519.2 million in Q4 2025, compared to -$4.8 million in Q3 2025 and $13.4 million in Q2 2025.